190 related articles for article (PubMed ID: 16648037)
1. Rituximab for early-stage diffuse large-B-cell lymphoma.
Friedberg JW
Lancet Oncol; 2006 May; 7(5):357-9. PubMed ID: 16648037
[No Abstract] [Full Text] [Related]
2. Rituximab in diffuse large B-cell lymphoma.
Coiffier B
Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943
[No Abstract] [Full Text] [Related]
3. Rituximab for bone lymphoma.
Savage DG; Staron R
Ann Intern Med; 2001 Jun; 134(12):1156-7. PubMed ID: 11412072
[No Abstract] [Full Text] [Related]
4. Rituximab for BCL-2-positive cancers.
Boughton B
Lancet Oncol; 2003 Feb; 4(2):69. PubMed ID: 12573343
[No Abstract] [Full Text] [Related]
5. CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).
Yokose N; Shioi Y; Sugisaki Y; Ohaki Y; Ogata K; Dan K
Leuk Lymphoma; 2006 Jul; 47(7):1415-7. PubMed ID: 16923582
[No Abstract] [Full Text] [Related]
6. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
Nakai S; Masaki T; Shintani T; Deguchi A; Kimura Y; Himoto T; Kurokohchi K; Watanabe S; Kuriyama S
Oncol Rep; 2005 Jun; 13(6):1065-8. PubMed ID: 15870922
[TBL] [Abstract][Full Text] [Related]
8. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
9. Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab.
Nagasaka A; Matsue H; Kawamura T; Kanzaki M; Inozume T; Nakamura Y; Shimzu A; Shibagaki N; Yanagi M; Shimada S
J Dermatol; 2006 May; 33(5):377-9. PubMed ID: 16700675
[No Abstract] [Full Text] [Related]
10. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).
Aboulafia DM
Am J Clin Oncol; 2001 Jun; 24(3):237-40. PubMed ID: 11404492
[TBL] [Abstract][Full Text] [Related]
11. Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma.
Shinohara A; Asai T; Izutsu K; Ota Y; Takeuchi K; Hangaishi A; Kanda Y; Chiba S; Motokura T; Kurokawa M
Leuk Lymphoma; 2007 Feb; 48(2):418-20. PubMed ID: 17325908
[No Abstract] [Full Text] [Related]
12. What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?
Crump M
Leuk Lymphoma; 2006 Dec; 47(12):2437-9. PubMed ID: 17169786
[No Abstract] [Full Text] [Related]
13. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
Lin PC; Hsiao LT; Poh SB; Wang WS; Yen CC; Chao TC; Liu JH; Chiou TJ; Chen PM
Ann Hematol; 2007 Feb; 86(2):95-100. PubMed ID: 17031689
[TBL] [Abstract][Full Text] [Related]
14. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R
Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581
[TBL] [Abstract][Full Text] [Related]
15. A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report.
Autorino R; Lamendola MG; De Sio M; Di Trolio RA; Ferraraccio F; Di Lorenzo G
Int J Immunopathol Pharmacol; 2007; 20(2):401-3. PubMed ID: 17624254
[TBL] [Abstract][Full Text] [Related]
16. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
[TBL] [Abstract][Full Text] [Related]
17. Diffuse large B-cell lymphoma.
Habermann TM
Clin Adv Hematol Oncol; 2005 Nov; 3(11):suppl 4-5. PubMed ID: 16491628
[No Abstract] [Full Text] [Related]
18. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
Ohguro N; Hashida N; Tano Y
Arch Ophthalmol; 2008 Jul; 126(7):1002-3. PubMed ID: 18625954
[No Abstract] [Full Text] [Related]
[Next] [New Search]
